Stock Events

Stock Events

Baudax Bio 

$0.000100
1
+$0.00+0% Monday 20:00

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0001
52W Low
0.00001
Volume
1
Avg. Volume
0
Mkt Cap
4,359.3
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22NovExpected
Q4 0
Q1 2024
Q2 2024
Q3 2024
-0.12
-0.11
-0.09
-0.08
Expected EPS
-0.09
Actual EPS
N/A

Financials

-4,633.18%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
1.27MRevenue
-58.8MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacira BioSciences
PCRX
Mkt Cap1B
Pacira Biosciences focuses on non-opioid pain management, directly competing with Baudax Bio's non-opioid analgesic offerings.
Trevena
TRVN
Mkt Cap9,501
Trevena, Inc. develops novel medicines for pain management, including oliceridine, a competitor to Baudax Bio's analgesic products.
Heron Therapeutics
HRTX
Mkt Cap78.44M
Heron Therapeutics focuses on improving the therapeutic profile of pain management products, directly competing with Baudax Bio's portfolio.
Nektar Therapeutics
NKTR
Mkt Cap2.38B
Nektar Therapeutics works on pain management therapies that could compete with Baudax Bio's non-opioid analgesic solutions.
Collegium Pharmaceutical
COLL
Mkt Cap1.14B
Collegium Pharmaceutical offers pain management solutions that could be seen as alternatives to Baudax Bio's products.
Evolus
EOLS
Mkt Cap429.37M
Evolus competes in the broader pharmaceutical market, indirectly competing with Baudax Bio's focus on pain management through its aesthetic medicine portfolio.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.81B
Supernus Pharmaceuticals has a focus on central nervous system diseases but also competes in the pain management market, overlapping with Baudax Bio's interests.

About

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Show more...
CEO
Dr. Geraldine A. Henwood Ph.D.
Employees
9
Country
United States
ISIN
US07160F4046

Listings

OTC Link
US
BXRXQ

0 Comments

Share your thoughts

FAQ

What is Baudax Bio stock price today?▼
The current price of BXRXQ is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Baudax Bio stock price performance more closely on the chart.
What is Baudax Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Baudax Bio stocks are traded under the ticker BXRXQ.
Is Baudax Bio stock price growing?▼
BXRXQ stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Baudax Bio has showed a +900% increase.
What is Baudax Bio market cap?▼
Today Baudax Bio has the market capitalization of 4,359.3
What is Baudax Bio revenue for the last year?▼
Baudax Bio revenue for the last year amounts to 1.27M USD.
What is Baudax Bio net income for the last year?▼
BXRXQ net income for the last year is -58.8M USD.
How many employees does Baudax Bio have?▼
As of July 19, 2026, the company has 9 employees.
In which sector is Baudax Bio located?▼
Baudax Bio operates in the Health & Wellness sector.
When did Baudax Bio complete a stock split?▼
Baudax Bio has not had any recent stock splits.
Where is Baudax Bio headquartered?▼
Baudax Bio is headquartered in Malvern, United States.